Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Non-Current Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 6772.5% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, up 6772.5% year-over-year, with the annual reading at $2.7 million for FY2025, 6772.5% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $2.7 million at Orchestra BioMed Holdings, up from $248000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $2.7 million in Q4 2025, with the low at $40000.0 in Q4 2024.
  • Average Other Non-Current Liabilities over 4 years is $676600.0, with a median of $248500.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities plummeted 60.1% in 2023, then skyrocketed 6772.5% in 2025.
  • Over 4 years, Other Non-Current Liabilities stood at $2.1 million in 2022, then tumbled by 87.27% to $266000.0 in 2023, then crashed by 84.96% to $40000.0 in 2024, then surged by 6772.5% to $2.7 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $2.7 million, $248000.0, and $189000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.